Efficacy of Jinhua Qinggan Granules (JHQG) for the Treatment of Upper Respiratory Infection: A Clinical Trial

Asadabad University of Medical Sciences0 个研究点目标入组 1,000 人开始时间: 待定最近更新: 2022年6月27日

适应症

试验速览

暂无简介。

•Body Temperature > 37.5ºC and highest point <39ºC within 24hours of enrollment,
•Within 12 hours of screening, three or more of the following main symptoms: Nasal Congestion, Rhinorrhea, Sore and/or scratchy throat, sneezing, headache, muscle or body aches, or malaise.
•The subject has signed the informed consent form.

•Other Respiratory diseases or acute and chronic nasal diseases or abnormal nasal mucosal function after nasal surgery or nasopharyngeal radiotherapy
•Severe primary health conditions associated with cardiovascular, cerebrovascular, pulmonary, hepatic, renal, endocrine and hematological diseases, hematopoietic system and mental illness or serious diseases affecting their survival, such as cancer or AIDS
•With severe cardiopulmonary dysfunction, cardiopulmonary insufficiency
•Subjects, who were treated with other Chinese and western drugs (including drugs for common cold, antiviral, antibiotics, and similar traditional Chinese medicine) and antipyretic and analgesic drugs within 6 hours before enrollment.
•Allergic individuals and those who are known to be allergic to experimental drugs.
•Pregnant women, and lactating women
•Subject, who has participated in the past 1 month in another clinical study.
•Subjects who are not suitable for the clinical trial based on investigators’ judgment.
•Subjects who consume alcohol.

发起方

Asadabad University of Medical Sciences